ZOGENIX, INC. (NASDAQ:ZGNX) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition.
On August8, 2017, Zogenix, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2017. A copy of this press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
|
Item 2.02 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release, dated August 8, 2017 |
ZOGENIX, INC. ExhibitEX-99.1 2 a6-30x2017exhibit991er.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsTop-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017Second Phase 3 Clinical Trial in Dravet Syndrome,…To view the full exhibit click here
About ZOGENIX, INC. (NASDAQ:ZGNX)
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.
